|No Photo on File||
Dr. Valery RadchenkoTRIUMF
Targeted Radionuclide Therapy (TRT) is a promising option for cancer treatment, even when other standard treatment options (e.g. surgery and chemotherapy) are not effective or suitable any more. TRT is based on a combination of therapeutic radionuclides (Î²-, alpha or Auger emissions) with selective biomolecules or polymers, which selectively deliver the chosen radionuclide to the tumor site. Several emissions are suitable for TRT including Î²-, which are currently used routinely for clinical applications. However, the main principle/benefit of TRT is maximizing damage of targeted cells with minimal damage of surrounding healthy tissues. In the case of Î²- emitters, all energy is deposited over a relatively long distance (several mm’s). From this perspective, alpha and Auger emitting radionuclides will be more efficient, which distributes all energy in relative proximity to the tumor cells with minimal effect on healthy tissues when delivered effectively. For alpha particles, a high energy compared to beta particles and Auger electrons make this therapy potentially very powerful. This lecture will provide overview of current and upcoming activities on production and application of various therapeutic radionuclides (e.g. 225Ac, 119Sb etc.) at TRIUMF
After receiving my PhD from the University of Mainz (Germany) in 2013, where I developed promising imaging candidate for immuno-PET (90Nb), I continued my research in development of therapeutic radiopharmaceuticals at Los Alamos National Laboratory (USA) as a postdoctoral researcher. My main duties were establishing radiochemical separation for several diagnostic (44ti/44Sc) and therapeutic (225Ac, 230Pa, 223Ra, 111Ag, 103mRh, 119Sb etc.) radionuclides. I was involved in all steps of design and testing of radiopharmaceuticals for targeted therapy from production to in vivo evaluation. I became a research scientist at TRIUMF (Canada) in 2016, where I am working on utilization of TRIUMF infrastructure for production of therapeutic radionuclides (e.g. 225Ac for target alpha therapy, 119Sb for auger therapy and others). I also working together with local and international collaboration partners on chelation, in vitro and in vivo application aspects.